Vitura Health Limited · ASX:VIT
Vitura Health — Investor Presentation (September 2024)
26 slides from Vitura Health's investor presentation, Sep 4, 2024
Slide 1: Investor webinar and presentation
ASX ANNOUNCEMENT Investor webinar and presentation 4 SEPTEMBER 2024 Melbourne, Australia – Vitura Health Limited (ASX: VIT) (Vitura and Company), a leading digital health platform business focused on innovating the delivery of healthcare by building a centralised healthcare experience that connects
Slide 2: About Vitura Health Limited
About Vitura Health Limited (ASX: VIT) www.vitura.com.au Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its wholly owned subsidiaries, operates the following businesses: • www.burleighheadscannabis.com Burleigh Heads Cannabis operates the market le
Slide 3: Authorised by / Contact / Forward-looking statements
Authorised by Robert Iervasi, Chair and Non-Executive Director Contact Vitura Health Limited Media enquiries Robert Iervasi Rebecca Harrison Chair The Civic Partnership 1300 799 491 +61 408 529 751 info@vitura.com.au rebecca. harrison@civicpartners.com.au Forward-looking statements This announcement
Slide 4: FY24 Full Year Results Investor Webinar
FY24 FULL YEAR RESULTS INVESTOR WEBINAR 4TH SEPTEMBER 2024 ROBERT IERVASI, INDEPENDENT CHAIR TOM HOWITT, INTERIM CEO Investor Presentation February 2023
Slide 5: Our future is focused on innovating the delivery of healthcare
Our future is focused on innovating the delivery of healthcare by building a centralised healthcare experience that connects and enhances each stage of the patient experience and journey throughout their lifetime. AGENDA • Company Overview • FY24 Highlights and Leadership • Operational Overview • De
Slide 6: Vitura overview
Vitura overview Vitura is a leading digital health platform business focused on innovating the delivery of healthcare through a centralised Company Information healthcare experience. Shares on issue 575,873,788 Our operations are divided into three segments allowing us to be involved and influence e
Slide 7: FY24 Highlights
FY24 HIGHLIGHTS
Slide 8: Focus on strengthening foundations to enable sustainable growth
Focus on strengthening foundations to enable sustainable growth ACQUISITION OF DOCTORS ON DEMAND LEADERSHIP EVOLUTION • $25M cash/debt/scrip acquisition. • Robert Iervasi appointed Independent Chair. • Strengthened and expanded telehealth platform • Geoffrey Cockerill appointed CEO. complementing CD
Slide 9: Importance of business diversity - a shifting environment
Importance of business diversity - a shifting environment Medicinal cannabis market has expanded, Adapting to the evolving needs of patients Pressures on health infrastructure driving but is now highly competitive patients online • Growing demand for medical • Australian medicinal cannabis industry
Slide 10: Strategy Reset – responding to a changing environment and declining financial performance
Strategy Reset – responding to a changing environment and declining financial performance STRENGTHEN MARKET EXPAND CUSTOMER AND TECHNOLOGY FINANCIAL POSITION MARKET BASE ENHANCEMENT IMPROVEMENT • Maintain market leadership • Increase customer • Enhance and expand • Disciplined approach to in medicin
Slide 11: FY24 financial results summary
FY24 financial results summary Key Points • Group operating revenue increased 5.6% despite a challenging environment. A$M FY24 FY23 • Only 8 months of Doctors on Demand results included but materially contributed to an 874% increase in clinical consulting revenue to $15.4M. Operating revenue 123.9 1
Slide 12: New leadership team focused on execution
New leadership team focused on execution Board Executive Team Robert Iervasi, Independent Non-executive Chair Geoffrey Cockerill, CEO • Appointed 12 February 2024 • Commencing 25 November 2024 • Previous roles: Diageo, Lion, Subway, Queensland Cricket and ATP Science. Guy Headley, Non-Executive Dire
Slide 13: Operational Overview
OPERATIONAL OVERVIEW
Slide 14: Vitura’s unique digital health ecosystem
Vitura’s unique digital health ecosystem Fully integrated end-to-end digital health platform with services at every step of the patient journey: • 24-hour telehealth services through Doctors on Demand. • Connecting more than 15,000 prescribers to healthcare products through Canview. • Distribution,
Slide 15: Acquisition of Doctors on Demand
Acquisition of Doctors on Demand • Acquired in October 2023 for $25M from cash reserves, debt and the issue of shares in Vitura. • In combination with CDA and Cannadoc, Vitura offers a modern, responsive and expanded telehealth service. • 28% increase in volume of monthly consultations since Vitura
Slide 16: Synergies already being realised
Synergies already being realised • CDA Clinics and Cannadoc realising operational efficiencies and economies of scale through digitisation utilising DoD technology. • More than 200 doctors and 227,000 patient consultations with a return rate of 55% across our combined clinics in FY24. Expect consult
Slide 17: Focus on improving efficiency and functionality of Canview
Focus on improving efficiency and functionality of Canview • Developing and improving the efficiency and functionality of Canview as a multisided platform facilitating interactions and the exchange of products and services between four key user groups - suppliers, prescribers, pharmacies and patient
Slide 18: Market leadership in medicinal cannabis and psychedelics
Market leadership in medicinal cannabis and psychedelics Leading supplier of medicinal cannabis First supplier of therapeutic MDMA • Record 998,038 units of medicinal cannabis sold in FY24. • Vitura’s 50:50 joint venture, Cortexa, with Canadian-based PharmAla Biotech Holdings Inc., is Australia’s le
Slide 19: Detailed Financials
n = = 1S) 2 < 2 x (=) Lu = < = lu a
Slide 20: Revenue and earnings
Revenue and earnings Total revenue $123.9M • Increasing contribution from Clinics in FY24, including DoD, Comprising: expected to drive further revenue growth in FY25. • Product sales of $108.5M • Diversified product portfolio to support growth in products and • Consulting and service fees of $15.4M
Slide 21: Cashflow and net cash
Cashflow and net cash June 2024 June 2023 • Strong historical cash generation supported acquisition of Doctors ($M) ($M) on Demand with $12.1M cash contribution. Cash flows from/(used in) operating activities • Cash outflows included the payment of $5.4M in dividends for Receipts from customers 131.
Slide 22: Balance sheet
Balance sheet June 2024 June 2023 • Cash declined in FY25 largely due to acquisition of DoD and payment of second annual ($M) ($M) dividend. Company maintained healthy cash balance of $11.35M as at 30 June 2024. Cash 11.35 18.85 Receivables 13.74 9.34 • Receivables balance includes $1.0M in tax that
Slide 23: Market guidance – FY25
Market guidance – FY25 • Increase the total revenue generated in FY24 by 10% through organic growth. • Improve the EBITDA margin generated in FY24 by 3% through organic growth. • Improve OPEX efficiency in FY25 by 10%. Vitura is pleased to report that, for the first two months of FY25, the Company’s
Slide 24: Investment thesis remains strong
Investment thesis remains strong • Proven delivery of initiatives and execution excellence in market. • Quality clinical care setting the benchmark for telehealth service delivery (not just issuing scripts). • Expanded clinics and doctors network representing a privileged route to market. • New vert
Slide 25: Disclaimer applying to this Presentation
Disclaimer applying to this Presentation The following disclaimer applies to this presentation (Presentation) You are therefore advised to read this disclaimer carefully before reading or making any other use of this Presentation or any information contained in this Presentation. This Presentation h
Slide 26: Vitura Health Limited ASX : VIT
vitura.com.au info@vitura.com.au VITURA HEALTH LIMITED ASX : VIT 1300 799 491
Vitura Health — Investor Presentation (September 2024) on 6ix